The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.
Foundation Venture Capital Group (FVCG), the corporate venturing affiliate of New Jersey Health Foundation, has invested $100,000 in Actinobac Biomed.
The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.
